Urologic diseases in America project: Benign prostatic hyperplasia
Urologic diseases in America project: Benign prostatic hyperplasia
复制标题
DOI：
10.1097/01.ju.0000155709.37840.fe
复制
发表时间：
2005-04-01
影响因子：
6.6
通讯作者：
Jacobsen, SJ
中科院分区：
文献类型：
--
作者：
Wei, JT;Calhoun, E;Jacobsen, SJ
目的：良性前列腺增生（BPH）是美国男性中最常见的良性肿瘤，是一种慢性疾病，与进行性下尿路症状有关，在生命的第七个十年中几乎影响四分之三的男性。2000年美国50 - 79岁的2700万白色男性中，估计约有650万人符合讨论治疗的标准。材料和方法：用于产生这些结果的分析方法已在前面描述。2000年，约有450万人次到医生办公室进行前列腺增生的初步诊断，约有800万人次进行前列腺增生的初步或二次诊断。同年，在美国非联邦医院的住院患者中进行了约87，400例BPH切除术。虽然在20世纪90年代，前列腺增生症的门诊就诊人数持续增加，但经尿道前列腺切除术的使用、住院治疗和住院时间却急剧减少。这些趋势反映了BPH医疗管理的变化，即越来越多地使用药物和微创治疗。在2000年的直接费用估计为1.1亿美元的前列腺增生症的治疗不包括门诊pharmacies.Conclusions：考虑到前列腺增生症的影响，生活质量和医疗保健成本在数百万美国男性，额外的研究风险因素，诊断和治疗资源的使用，有效性和成本效益的治疗是必要的。
Purpose: Benign prostatic hyperplasia (BPH), the most common benign neoplasm in American men, is a chronic condition that is associated with progressive lower urinary tract symptoms and affects almost 3 of 4 men during the seventh decade of life. Approximately 6.5 million of the 27 million white men who are 50 to 79 years old in the United States in 2000 were estimated to meet the criteria for discussing treatment.Materials and Methods: The analytical methods used to generate these results have been described previously.Results: In 2000 approximately 4.5 million visits were made to physician offices to for a primary diagnosis of BPH and almost 8 million visits were made with a primary or secondary diagnosis of BPH. In the same year approximately 87,400 prostatectomies for BPH were performed in inpatients in nonfederal hospitals in the United States. While the number of outpatient visits for BPH increased consistently during the 1990s, there was a dramatic decrease in the use of transurethral prostatectomy, inpatient hospitalization and length of hospital stay for this condition. These trends reflect the changing face of medical management for BPH, ie increasing use of pharmacological agents and minimally invasive therapies. In 2000 the direct cost of BPH treatment was estimated to be $1.1 billion exclusive of outpatient pharmaceuticals.Conclusions: Given the impact that BPH has on quality of life and health care cost in millions of American men, additional research into risk factors, diagnostic and therapeutic resource use, and effectiveness and cost benefit of therapies are warranted.